摘要
目的为临床肝移植患者抗移植排斥反应药物的合理应用提供参考。方法采用微粒子酶免疫法(MEIA)对肝移植患者进行他可莫司血药浓度测定,并对结果进行分析。结果为6例肝移植患者检测他可莫司血药浓度77例次,质控结果均在有效范围内。肝移植术后他可莫司全血血药浓度在10-20μg/L范围内的占30.6%。结论为用药安全有效,应对肝移植患者监测FK506血药浓度,实行个体化给药。
Objective To give some information for rationally administrating oral FKS06 to liver wamplant patients in clinical. Methods The whole blood concentration of FK506 on 6 liver transplant patients was determined by mieo - particle enzyme immavnoassy (MEIA), the results and therapeutic effect were studied. Results There were 77 cases in 6 liver transplant patients detemained FK506 concentration, the quality control of MEIA was in effective level, The whole blood with effective level( 10- 20μg/L) were accounted for 30.6 %. Conclusion To be safe and effective for clinical use, it is important for liver transplant patients to monitor whole blood concentrations of FK506 with individualized drug administration.
出处
《宁夏医学杂志》
CAS
2006年第3期168-169,共2页
Ningxia Medical Journal